Vir Biotechnology, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 11.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.99B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Details
| Name | Vir Biotechnology, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 367 |
| Founded | 2016 |
| Ipo Date | 2019-10-11 |
| Ceo | Marianne De Backer |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 20.00 |
| Isin | US92764N1028 |
| Cusip | 92764N102 |
| Cik | 1706431 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | President, Chief Executive Officer and Director |
| Vanina de Verneuil J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Dr. Lawrence Corey M.D. | Co-Founder and Scientific Advisor |
| Dr. Louis J. Picker M.D. | Co-Founder and Scientific Advisor |
| Aziz Sawaf C.F.A., M.B.A. | Executive Vice President, Chief Financial Officer and Principal Financial Officer |
| Brent Sabatini C.P.A., M.B.A. | Senior Vice President, Principal Accounting Officer and Chief Accounting Officer |
| Dr. Maninder Hora Ph.D. | Executive Vice President and Chief Technical Operations Officer |
| Dr. Jennifer Eileen Towne Ph.D. | Executive Vice President and Chief Scientific Officer |
| Dr. Kiki Patel Pharm.D. | Head of Investor Relations |
| Carolyn Wang | Senior Vice President of Corporate Communications |
Contact
| Address | 1800 Owens Street, Suite 900, San Francisco, California 94158, United States |
| Phone | 415 906 4324 |
| Website | https://www.vir.bio |